Aralez Pharma (ARLZ) Misses Q2 EPS by 5c

Aralez Pharma (NASDAQ: ARLZ) reported Q2 EPS of ($0.27), $0.05 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $11.93 million.

For earnings history and earnings-related data on Aralez Pharma (ARLZ) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery